Loading...

KALV KALVISTA PHARMACEUTICALS INC Management Changes 8-K Filing

KLVS

KLV

KALVISTA PHARMACEUTICALS INC

(KALV)

2024 8-K

Show Summary

Show Summary

License Agreement

Fiscal Year Change

Financial Results

Management Change

Financial Results

Board Appointment

Revenue Rights Sale

Annual Meeting Results

Management Changes

Financial Results

Lease Agreement

Financial Results

Financial Results

Public Offering

Termination of Sales Agreement

Clinical Data Announcement

Financial Results

Amendment to Certificate of...

Financial Results

Amended Employment Agreement

Financial Results

Appointment of President

External Links:

KalVista Pharmaceuticals appointed Brian Piekos as Chief Financial Officer with a salary of $460,000, a 40% bonus target, and stock options for 100,000 shares; existing executives also updated their employment agreements without salary changes.

AI Assistant

KALVISTA PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.